Tag:
Micromet
Latest Headlines
Latest Headlines
Ex-Amgen research czar Perlmutter to helm Merck's struggling R&D ops
Roger Perlmutter is back. About a year after the Amgen R&D chief was squeezed out in a top-level reshuffling at the big biotech, Merck says they have tapped him to run the Big Pharma's research house, which has been consuming $8 billion a year without a lot to show for it.
UPDATED: Amgen scoops up Micromet tumor-fighting pipeline for $1.2B
Not to be left out of the M&A rush, Amgen said this morning that it will buy German/U.S. cancer drug developer Micromet ( $MITI ) for $1.16 billion in cash. At $11 a share, the deal gives its
Amgen widens cancer reach in $1B-plus Micromet deal
Amgen, the world's largest biotech, is firing up another deal to advance its expanded emphasis on cancer drug development. The biotech Micromet says that Amgen has become its latest major partner in
Micromet drug shows promise against severe blood cancer
While there's a way to go in proving the mettle of the drug, Micromet's experimental antibody blinatumomab wiped out cancer cells in nine of 12 patients with relapsed acute lymphoblastic leukemia
Micromet takes back MedImmune's blinatumomab rights
Bethesda, MD-based Micromet has agreed to buy out MedImmune's North American rights to blinatumomab , a potential treatment for lymphoma and leukemia. As a result of the buyout, Micromet now controls
Micromet inks $475M antibody deal with Sanofi
In a big endorsement of Micromet's approach to developing antibodies for cancer, Sanofi-Aventis has signed off on a $475 million deal that starts small but can lead to a series of rich prices for the
Micromet raising up to $80M to fund acquisitions, research
In a new sign that investors may be warming to biotech stock offerings, Micromet has outlined plans to raise between $70 million and $80 million from the sale of up to 16.1 million shares. The news
Micromet gets $40M in private placement
Bethesda, MD-based Micromet has closed its previously-announced $40 million private placement financing. Index Ventures Growth, Abingworth, DAFNA Capital Management and Merlin Nexus participated in
Micromet's blinatumomab shows promise in Phase I
It may be an early-stage study, but Micromet's antibody drug blinatumomab is showing promise for non-Hodgkin's lymphoma patients. In a Phase I study, all seven participants responded to the drug,
ALSO NOTED: FDA panelist rails against lax enforcement; Micromet's CFO resigns;and much more...
> Remember that scathing report from the FDA's own Subcommittee on
